Resistance of Plasmodium falcipanrm to chloroquine has been documented in most countries where there is transmission, over the last 2 decades (PETERS, 1987; PAYNE, 1989) . Resistance to other antimalarials has followed in many countries. This article will focus on resistance occurring in chemotherapy rather than prophylaxis. Host factors, including pharmacokinetics and immunity, will not be reviewed. Pyrimethamine and proguanil Resistance of P. falciparum to pyrimethamine develops rapidly and, described first in 1953, is now widespread (ONORI, 1984) . Resistance to pyrimethamine has been assessed mainly in terms of its activity against asexual parasites, but resistance at the preerythrocytic stage has also been reported (NAHLEN et al., 1989) . Resistance of the asexual blood stage to proguanil was also detected early (EDESON, 1950) , and the lack of prophylactic efficacy was recently confirmed in Thailand (PANG et al., 1989) . Cross resistance between antifols has been shown in vitro, but while there is a 750-fold difference in mean 50% inhibitory concentration (IC50) values between pyrimethamine-resistant and pyrimethamine-sensitive parasites, the corresponding figure for cycloguanil, the active metabolite of proguanil, was only 7.7-fold (WATKINS et al., 1987a) . Since the causal prophylactic effect is considered stronger than the therapeutic effect (DAVEY & ROBERTSON, 1957) , proguanil may still play a useful role in prophylaxis in areas with resistance to pyrimethamine. In Africa one recent study showed daily proguanil had significant prophylactic effect in Kenya (NEVILL et al., 1988) . In contrast, weekly chlorproguanil showed little efficacy in Burundi and in Kenya (COOSEMANS et al., 1987; WATKINS et al., 1987b) . This may, however, partly be due to inadequate dosing, as twice weekly dosing was fully effective in Tanzanian schoolchildren (ROOTH et al., 1990 ).
Chloroquine
The spread of chloroquine-resistant P. falciparum (CRPF) has been documented bv PAYNE (1989) . Countries with CRPF in the 1960s now report very high levels of resistance; for example, up to 85% in Brazil (KREMSNER et al., 1989) , 50% in Venezuela (MAYNADIE et al., 1989) , and over 90% in Thailand and Vietnam (PETERS, 1987) . A more recent phenomenon in Africa, CRPF has evolved rapidly throughout the region. Resistance was first reported in non-immunes returning from East Africa; resistCorrespondence to Dr Bjiirkman, Roslagstull Hospital.
ante in semi-immunes was reported 3 years later (KIHAMIA & GILL, 1982) . In subsequent reports from East Africa, drug failure rates have varied between 10% (WATKINS et al., 1987~) and 90% (HELLGREN et al., 1989; BRASSEUR et al., 1988) , with differences in parasite susceptibility reported within countries (KILIMALI & MKUFYA, 1985a) . A rapid increase in both frequency and level of CRPF has often been observed; for example in Madagascar and Somalia (WARSAME et al., 1990) . In Central and Southern Africa, around 70% failure rates have been repeatedly reported from Rwanda (SEXTON et al., 1988; GARCIA-VIDAL et al., 1989) , and between 10% and 45% in Zambia (LEMNGE & INAMBAO, 1988) . Recently there has been a rapid decline in the sensitivity of I'. falciparum to chloroquine in West Africa, and 10% to 25% failure rates are now reported in Nigeria (LEGE-OGUNTOYE et al., 1989; DANIEL & MOLTA. 1989) and Benin (CHIPPAUX et al., 1989) .
Amodiaquine
Although at first CRPF strains retained some sensitivity to another 4 aminoquinoline, amodiaquine , resistance to this drug followed development of chloroquine resistance (DRAPER et al., 1988; LEMNGE & INAMBAO, 1988; KREMSNER et al., 1989) .
Sulfadoxinelpyrbnethamine
Resistance to sulfadoxineipyrimethamine (SP) has been reported mainly in areas of intense use, particularly Thailand and Kampuchea. It was fully effective in Kampuchea only until the mid 1960s (VERDRAGER et al., 1967) . By the mid 1970s treatment failures at the RI11 level also occurred in Thailand (DOBERSTYN et al., 1976) , and by the early 1980s drug failure rates were up to 90% (PINICHPONGSE et al., 1982) . Reports from Indonesia, Papua New Guinea, China and Pakistan also illustrate some resistance (QILIN et al., 1988; STRICKLAND et al., 1986 ). There were early reports of resistance to SP from Brazil, and recently 23125 isolates were resistant in vitro (KREMSNER et al., 1989) . Venezuela has also reported resistant infections (MAYNADIE et al., 1989) .
Numerous sentinel cases of resistance to SP have been reported in non-immunes visiting Africa during the 1980s (PETERS, 1987; WERNSDORFER & PAYNE, 1990) . In Rwanda, clinical trials in individuals with low immunity showed 2154 and 18/53 failures in 1985 and 1987 respectively (GARCIA-VIDAL et al., 1989) . Clinical trials in semi-immune Africans have shown higher success rates (PETERS, 1987) , although 2 studies from Tanzania revealed some failures (KILI- MALI & MKUFYA, 1985b; DRAPER et aE., 1988) . Poor bioavailability may have been partly responsible for drug failures (WHO, 1984) . However, in Kenya, when 5135 semi-immunes failed to respond, these failures were confirmed in vitro . Similarly, 2 failures in non-immunes were also confirmed in vitro, and adequate drug levels were also observed (SCHAPIRA et al., 1986) . In contrast, in a recent in vitro study in Somalia all isolates were sensitive (WARSAME et al., 1990) .
Quinine
Quinine has remained the main therapeutic drug for CRPF malaria althoueh low sensitivitv was reported in Brazil as early al 1910. Quinine has been used extensively in south-east Asia, where resistance to chloroquine and SP is especially high. Cure rates with quinine have now fallen substantially in some areas, even below 50% (BUNNAG & HARINASUTA, 1987; GIBODA & DENIS, 1988 BRASSEUR et al., 1987 BRASSEUR et al., , 1988 .
Mefiquine
Clinical trials of mefloquine, conducted in the 198Os, have shown high efficacy (98%100%) in Zambia, Brazil, Burma, and Thailand (WHO, 1984) . Resistance in non-immune individuals has, however, been reported from Thailand (BOUDREAU et al., 1982; KARWACKI et al., 1989) , Tanzania (BYGBJERG et aE., 1983) , and West Africa (RINGWALD et al., 1990) , with some in vitro IC50 values of 4&80 nmol/litre. One report suggested that resistance was enhanced by treatment (BYGBIERG et al., 1983) . which would confirm the' tendency to development of resistance to mefloquine under drug pressure observed in rodent malaria (PETERS et al, -1977) .
One in vitro studv from Thailand indicated a shift towards higher resistance, with mean IC50 increasing from 11 to 17 nmohlitre between 1982 and 1984? with a simultaneous decrease in quinine susceptibility (SUEBSAENG et al., 1986) . With an MIC value of 320 nmoVlitre indicative of resistance, a study in Kampuchea showed 25/26 isolates to be sensitive (GIBODA & DENIS, 1988) . In South America and Africa, field studies'have confirmed between 97% and 100% susceutibilitv in vitro in Tanzania (DRAPER et _.. KILIMALI ef al., 1989) , Gabon (BURCHARD et al., 1984) , Benin (CHIPPAUX et al., 1989) , Somalia (WARSAME et al., 1988 ), Brazil (KREMSNER et al., 1989 , and Venezuela (MAYNADIE et al., 1989) . Full sensitivity was also confirmed in Vanuatu (BASTIEN, 1989) . The poor sensitivity (10115) reported in Iran was because a low concentration was taken as the threshold of resistance (EDRISSIAN et al., 1989) .
In contrast to these results, and using other criteria, 2 recent studies have claimed reduced susceptibility in West Africa. One studv renorted lower IC50 values. between 20 and 55 r&oYl&re, for seven isolates in continuous culture originating from Liberia, Nigeria, and Sierra Leone. CornDared with IC50 values between 3 and 19 r&ol/liire for 5 isolates from other parts of the world (ODUOLA et al., 1987) . Decreased mefloquine susceptibility was also suggested in Mali and Senegal, with mean IC50 values of 30 and 21 nmol/litre, compared with 10 to 20 nmohlitre in 8 other African countries (SIMON et al., 1988 Coosemans, M. H., Barutwanayo, M., Onori, E., Otoul, C., Gryseels, B. & W&y, M. (1987) . Double blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cyclogutil. ._
